FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554484156> ?p ?o ?g. }

• W2554484156 endingPage "99" @default.
• W2554484156 startingPage "98.2" @default.
• W2554484156 abstract "<h3>Background</h3> Two phase 3 clinical trials, MEASURE 1 and 2, demonstrated the efficacy of secukinumab for active ankylosing spondylitis (AS). However, there is limited data comparing the efficacy of secukinumab with established AS treatments. <h3>Objectives</h3> The objective of this study was to compare relative efficacy between adalimumab and secukinumab, estimate the number needed to treat (NNT), and evaluate the incremental cost per responder (CPR) for the treatment of active AS. <h3>Methods</h3> An indirect comparison was conducted using individual patient data from the adalimumab clinical trial (ATLAS)¹ and published data from the secukinumab trials (MEASURE 1 and 2).² Only dosages approved by the European Medicines Agency (adalimumab 40mg and secukinumab 150mg) were included in the analysis. To adjust for the cross-trial differences, individual patients in ATLAS were re-weighted to match the mean baseline characteristics in the MEASURE trials.^3,4 Specifically, age, weight, gender, duration of AS, baseline methotrexate use, baseline sulfasalazine use, presence of positive HLA-B27, BASDAI score and total back pain score were included in the baseline matching. The ASAS20, ASAS40 and ASAS 5/6 response rates relative to placebo at the end of the trial period (adalimumab: 12 weeks, secukinumab: 16 weeks) were compared. NNTs to achieve one additional ASAS20, ASAS40 and ASAS 5/6 responder and the corresponding incremental CPRs were also calculated. Drug costs in terms of 2015 Euros were obtained from the Lauer Taxe.⁵ <h3>Results</h3> After matching, mean baseline characteristics were balanced across the ATLAS and MEASURE 1 and 2 populations. Compared to secukinumab (n=197), adalimumab (n=204) demonstrated similar efficacy in ASAS20/40 and ASAS 5/6. The mean differences (95% confidence interval) between adalimumab and secukinumab in relative ASAS20, ASAS40 and ASAS 5/6 response rates were 2.3% (-12.8%, 17.5%), -0.4% (-14.1%, 13.4%), and -3.1% (-17.3%, 11.2%), respectively. The NNTs to achieve one additional responder were also comparable between adalimumab and secukinumab: 2.9 vs 3.1 in ASAS20, 3.7 vs 3.7 in ASAS40, and 3.1 vs 2.8 in ASAS 5/6. Incremental CPRs relative to placebo were lower for adalimumab compared to secukinumab across all efficacy measures (Figure 1). <h3>Conclusions</h3> In the absence of head to head trials comparing adalimumab and secukinumab, the current indirect comparison reduced cross-trial differences and provides timely and reliable evidence for physicians and payers. After adjusting for cross-trial differences in baseline characteristics, adalimumab demonstrated similar efficacy as secukinumab in terms of ASAS20, ASAS40 and ASAS 5/6 responses and was associated with lower incremental CPR compared with secukinumab over the trial period among patients with active AS. <h3>References</h3> van der Heijde D, et al. Arthritis Rheum. 2006;54:2136–46. Baeten D, et al. N Engl J Med. 2015;373:2534–48. Signorovitch JE, et al. Pharmacoeconomics. 2010;28:935–45. Signorovitch JE, et al. Value Health. 2012;15:940–7. http://www.lauer-fischer.de.Accessed December 2015. <h3>Disclosure of Interest</h3> K. Betts Consultant for: AbbVie, M. Mittal Shareholder of: AbbVie, Employee of: AbbVie, J. Song Consultant for: AbbVie, M. Skup Shareholder of: AbbVie, Employee of: AbbVie, A. Joshi Shareholder of: AbbVie, Employee of: AbbVie" @default.
• W2554484156 created "2016-11-30" @default.
• W2554484156 creator A5046483647 @default.
• W2554484156 creator A5065311807 @default.
• W2554484156 creator A5068637941 @default.
• W2554484156 creator A5079729596 @default.
• W2554484156 creator A5082155253 @default.
• W2554484156 date "2016-06-01" @default.
• W2554484156 modified "2023-10-03" @default.
• W2554484156 title "OP0115 Relative Efficacy of Adalimumab versus Secukinumab in Active Ankylosing Spondylitis: A Matching-Adjusted Indirect Comparison" @default.
• W2554484156 doi "https://doi.org/10.1136/annrheumdis-2016-eular.2754" @default.
• W2554484156 hasPublicationYear "2016" @default.
• W2554484156 type Work @default.
• W2554484156 sameAs 2554484156 @default.
• W2554484156 citedByCount "3" @default.
• W2554484156 countsByYear W25544841562018 @default.
• W2554484156 countsByYear W25544841562020 @default.
• W2554484156 countsByYear W25544841562021 @default.
• W2554484156 crossrefType "journal-article" @default.
• W2554484156 hasAuthorship W2554484156A5046483647 @default.
• W2554484156 hasAuthorship W2554484156A5065311807 @default.
• W2554484156 hasAuthorship W2554484156A5068637941 @default.
• W2554484156 hasAuthorship W2554484156A5079729596 @default.
• W2554484156 hasAuthorship W2554484156A5082155253 @default.
• W2554484156 hasConcept C126322002 @default.
• W2554484156 hasConcept C142724271 @default.
• W2554484156 hasConcept C204787440 @default.
• W2554484156 hasConcept C27081682 @default.
• W2554484156 hasConcept C2776260265 @default.
• W2554484156 hasConcept C2777077863 @default.
• W2554484156 hasConcept C2777402515 @default.
• W2554484156 hasConcept C2777453003 @default.
• W2554484156 hasConcept C2777575956 @default.
• W2554484156 hasConcept C2779786854 @default.
• W2554484156 hasConcept C2780132546 @default.
• W2554484156 hasConcept C535046627 @default.
• W2554484156 hasConcept C71924100 @default.
• W2554484156 hasConceptScore W2554484156C126322002 @default.
• W2554484156 hasConceptScore W2554484156C142724271 @default.
• W2554484156 hasConceptScore W2554484156C204787440 @default.
• W2554484156 hasConceptScore W2554484156C27081682 @default.
• W2554484156 hasConceptScore W2554484156C2776260265 @default.
• W2554484156 hasConceptScore W2554484156C2777077863 @default.
• W2554484156 hasConceptScore W2554484156C2777402515 @default.
• W2554484156 hasConceptScore W2554484156C2777453003 @default.
• W2554484156 hasConceptScore W2554484156C2777575956 @default.
• W2554484156 hasConceptScore W2554484156C2779786854 @default.
• W2554484156 hasConceptScore W2554484156C2780132546 @default.
• W2554484156 hasConceptScore W2554484156C535046627 @default.
• W2554484156 hasConceptScore W2554484156C71924100 @default.
• W2554484156 hasIssue "Suppl 2" @default.
• W2554484156 hasLocation W25544841561 @default.
• W2554484156 hasOpenAccess W2554484156 @default.
• W2554484156 hasPrimaryLocation W25544841561 @default.
• W2554484156 hasRelatedWork W2052900499 @default.
• W2554484156 hasRelatedWork W2462554540 @default.
• W2554484156 hasRelatedWork W2754678896 @default.
• W2554484156 hasRelatedWork W2765262888 @default.
• W2554484156 hasRelatedWork W2890735434 @default.
• W2554484156 hasRelatedWork W2906115491 @default.
• W2554484156 hasRelatedWork W3046824218 @default.
• W2554484156 hasRelatedWork W3109111838 @default.
• W2554484156 hasRelatedWork W3158903450 @default.
• W2554484156 hasRelatedWork W4246025416 @default.
• W2554484156 hasVolume "75" @default.
• W2554484156 isParatext "false" @default.
• W2554484156 isRetracted "false" @default.
• W2554484156 magId "2554484156" @default.
• W2554484156 workType "article" @default.